Medivir Abandons Separate Listing, Sells Off Commercial Unit

01 Nov 2016

• By Sukaina Virji

Medivir has decided a sale of its commercial arm BioPhausia makes better business sense than a separate listing, and is selling the unit to Karo Pharma for just over $100m.

Amid tough market conditions, Medivir AB CEO Niklas Prager is "convinced" that a sale of its Nordic Brands portfolio – operating as BioPhausia AB – to Karo Pharma "is the best way to maximize the value for our shareholders." He had been considering a separate listing on First North Premium, NASDAQ's European market for smaller, growing companies. (Also see "Medivir Plans For A Post-Simeprevir Future" - Scrip, 31 August, 2016.)

The SEK908m ($101m) cash and debt free sale to Karo Pharma means the commercial unit "can continue its positive development...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

27 Jun 2025

• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

27 Jun 2025

• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.